As reported on BioPharmaDive, UCB has reported positive results from a head-to-head clinical trial showing that its anti-inflammatory biologic Bimzelx was more effective than AbbVie’s Skyrizi in patients with active…
Editor's Note: Patient Worthy is proud and honored to share Jennifer's story with cystic fibrosis and colon cancer, originally published on the Cystic Fibrosis Research Institute's website. It started like…
The biotechnology sector experienced significant positive developments this week, with Xenon Pharmaceuticals' seizure medication achieving a decisive late-stage victory while regulatory pathways accelerated for several other promising therapies. According to…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
